title: [New Developments in CKD-MBD. New aspects in phosphate binders].
abstract: In patients with end-stage renal disease (ESRD) , hyperphosphatemia contributes to secondary hyperparathyroidism and can lead to skeletal complications including fracture, and vascular calcification. Currently employed phosphate binders include calcium carbonate, sevelamer hydrochloride, and lanthanum carbonate. While these agents are effective at binding orally ingested phosphates, they vary in safety, potency, and off-target effects, some of which may be salutary (e.g., low-density lipoprotein and uric acid lowering with sevelamer) and others adverse (low turnover bone disease and progressive vascular calcification with calcium) . There remains a large unmet need for safe and effective phosphate binders with favorable off-target effects.
authors.affiliation: Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
authors.forename: Keitaro
authors.initials: K
authors.lastname: Yokoyama
mesh_terms: D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000209:etiology; D002614:Chelating Agents / Q000627:therapeutic use*; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000517:prevention & control; D010710:Phosphates / Q000378:metabolism*; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000378:metabolism*; D061205:Vascular Calcification / Q000188:drug therapy / Q000517:prevention & control
chemical_list: D002614:Chelating Agents; D010710:Phosphates; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23